Actively Recruiting
Observational Registry to Evaluate Safety and Performance of the Minos Abdominal Aortic Stent-Graft System for Treating Abdominal Aortic Aneurysms in European and Asian Hospitals
Led by Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd · Updated on 2026-06-29
200
Participants Needed
16
Research Sites
221 weeks
Total Duration
AI-Summary
What This Trial Is About
This observational study evaluates the Minos4 Abdominal Aortic Stent-Graft and Delivery System, a medical device used to treat abdominal aortic aneurysms through a minimally invasive procedure. The device is inserted into the aorta via blood vessels, typically through small groin incisions. The study aims to collect short-, medium-, and long-term safety and performance data from about 200 patients worldwide, including at least 30 patients in European hospitals. Participants in this study will be treated with the Minos4 stent-graft system as part of their usual medical care. The treatment involves implanting the device to repair the aneurysm, with follow-up care conducted according to each institutions standard practices. The study focuses on real-world use of the device, observing outcomes over time. During the study, participants will be monitored for technical success at 12 months and assessed for various outcomes such as adverse events within 30 days, aneurysm treatment success over 2 to 5 years, mortality rates, secondary interventions, aneurysm size changes, and device-related complications. This follow-up can continue for up to five years after the procedure to gather comprehensive safety and performance information.
CONDITIONS
Brief Title
Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment
Research Team
M
Maggie Shen, MD MSc
A
Anne Woodman
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here